Quarterly UpdatesApr 16, 2026, 05:02 PM
Sanuwave Reports Preliminary Q1 Revenue of $9.6M-$9.7M
AI Summary
Sanuwave Health announced preliminary revenues for the first quarter ended March 31, 2026, are expected to be in the range of $9.6 million to $9.7 million. This represents a 3-4% increase over Q1 2025 and is in line with the company's prior guidance. CEO Morgan Frank stated that while some deals shifted out of the quarter, bringing results to the lower end of guidance, the company remains optimistic about its Ultramist product despite market challenges in wound care reimbursement.
Key Highlights
- Preliminary Q1 2026 revenue: $9.6M to $9.7M.
- Revenue increased 3-4% over Q1 2025.
- Revenue is within prior Q1 guidance range.
- CEO noted deals slid out, impacting Q1 results.